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Once considered merely as a neurotransmitter, serotonin (5-HT) now enjoys 
a renewed reputation as an interlocutor in the dense and continuous dialogue 
between neuroendocrine and immune systems. In the last decades, a role has been 
depicted for serotonin and its derivatives as modulators of several immunological 
events, due to the expression of specific receptors or enzymes controlling 5-HT 
metabolism in diverse immune cell types. A growing body of evidence suggests that 
the effects of molecules belonging to the 5-HT pathways on the neuroimmune com-
munication may be relevant in the clinical outcome of autoimmune/inflammatory 
pathologies of the central nervous system (CNS), such as multiple sclerosis, but 
also in Alzheimer’s disease, or in mood disorders and major depression. Moreover, 
since the predominance of 5-HT is produced by enterochromaffin cells of the 
gastrointestinal tract, where 5-HT and its derivatives are important mucosal signal-
ling molecules giving rise to the so-called “brain-gut axis”, alterations in brain-gut 
communication are also involved in the pathogenesis and pathophysiology of 
several psychiatric and neurologic disorders. Here we illustrate how functional 
interactions between immune and neuronal cells are crucial to orchestrate tissue 
homeostasis and integrity, and the role of serotonin pathway components as pillars 
of the neuroimmune system.
Keywords: neuroimmune system, tryptophan metabolism, serotonin, 
N-acetylserotonin, melatonin, indoleamine 2,3-dioxygenase
1. Introduction
It’s now widely accepted that the immune system and neuroendocrine system 
function in close association of each other, to such an extent that it’s possible to refer 
to them as “neuroimmune system” [1]. The interactions that take place within the 
neuroimmune system involve the production and use of immune factors, as well as 
neuroendocrine mediators, in a role-playing game where it’s impossible to trace the 
belonging of specific molecules exclusively in one of the two systems. The constant 
dialogue between the participants to the neuroimmune communication in the CNS 
and in the periphery not only allows the fine tuning of the immune response, but 
also the synaptic plasticity, and alterations in the propagation of neuroimmune 
messages may account for several immune-mediated and psychiatric diseases.
Here we examine the role of serotonin and its derivatives in the neuroimmune 
communication and we highlight the importance of an appropriate balance between 
the production of tryptophan metabolites for the maintenance of the neuroimmune 
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homeostasis. Moreover, we give a perspective on how the regulation of the meta-
bolic pathways leading to different tryptophan metabolites, including serotonin 
and derived molecules, could represent a significant pharmacological target for the 
treatment of various CNS diseases.
2. Serotonin pathway in the neuroimmune system: an overview
Under physiological conditions, the majority of Tryptophan (Trp) is degraded 
along the kynurenine pathway (KP) and only about 1% is metabolized into sero-
tonin (5-HT) in the so-called methoxyindoles pathway (Figure 1). This metabolic 
route begins with the transformation of Trp into 5-hydroxytryptophan and then 
into serotonin through two consecutive reactions catalyzed by the enzymes tryp-
tophan hydroxylase (TPH) and 5-hydroxytryptophan decarboxylase (AADC). 
Subsequently, the rate-limiting enzyme arylalkylamine N-acetyltransferase 
(AANAT) promotes the acetylation of serotonin into N-acetylserotonin (NAS), 
which, in turn, serves as a substrate for the hydroxyindole-O-methyl transferase 
(HIOMT or acetylserotonin O-methyltransferase, ASMT) to generate melatonin. 
Then, melatonin can be cleaved by indoleamine 2,3-dioxygenase 1 (IDO1) in a non-
specific reaction and transformed into N-acetyl-N-formyl-5-methoxykynurenamine 
(AFMK). Additional enzymatic or oxidative pathways other than IDO1 are respon-
sible for the generation of AFMK from the common precursor. Specifically, AFMK 
can arise from reaction of melatonin with hydroxyl radical and the subsequent 
interaction of the new-born melatonyl species with superoxide anion [2]. Moreover, 
Figure 1. 
Tryptophan metabolism along the kynurenine, serotonin and indole pathways. The majority of tryptophan 
is converted into kynurenine, whereas only about 1% is metabolized into serotonin. A small amount of 
tryptophan is used by the gut microbiota to produce indole derivatives. AADC, aromatic amino acid 
decarboxylase; AANAT, arylalkylamine N-acetyltransferase; ALDH, aldehyde dehydrogenase; AFMK, 
acetyl-N-formyl-5-methoxykynurenamine; ArAT, acromatic amino acid aminotransferase; ASMT, 
N-acetylserotonin O-methyltransferase; 3-HAA, 3-hydroxyanthranilic acid; 3-HK, 3-hydroxykynurenine; 
5-HTTP, 5-hydroxytryptophan; IA, indoleacrylic acid; IAA, indoleacetic acid; Iald, indole-3-aldehyde; IAAld, 
indole-3-acetaldehyde; IAM, indole-3-acetamide; IDO1, indoleamine 2–3-dioxygenase 1; ILA, indolelactic 
acid; INMT, indolethylamine-N-methyltransferase; IPA, indole-3-propionic acid; IPYA, Indole-3-pyruvate; 
KAT, kynurenine aminotransferase; KMO, kynurenine-3-monooxygenase; KYNU, kynureninase; MAO, 
monoamine oxidase; NAD+, nicotinamide adenine dinucleotide; NAS, Nacetylserotonin; TDO2, tryptophan 
2,3-dioxygenase; TMO, tryptophan 2-monooxygenase; TPH, tryptophan hydroxylase.
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melatonin can yield to AFMK either by directly scavenging hydrogen peroxide or 
serving as a substrate of neutrophils’ myeloperoxidase [3, 4].
Serotonin is a double life metabolite acting as neurotransmitter and peripheral 
hormone [5]. As a matter of fact, about 5% of the total serotonin is synthesized by 
serotoninergic neurons and operates within the CNS, while the majority of human 
body’s serotonin is produced by enterochromaffin cells (EC) located in the gastro-
intestinal tract (GI). A significant amount of gut serotonin is released in the blood-
stream where it is rapidly absorbed and stored by platelets and, to a lesser extent, by 
immune cells [6]. Although both TPH and AADC are necessary for the production 
of serotonin, TPH is the rate-limiting enzyme, as demonstrated by its weak affinity 
for any other amino acid and by the reduced serotonin levels upon pharmacologic or 
genetic ablation of the enzyme [7]. TPH exists into two isoforms that mainly differ 
in terms of cellular localization, i.e. TPH1- expressed by EC cells - and TPH2, found 
in central neurones [8].
The balance between the biosynthesis and the metabolism affects the bioavail-
ability of serotonin. Indeed, besides the main branch of methoxyindoles pathway 
that yields to AFMK as end product, three additional catabolic reactions are respon-
sible for the biotransformation of serotonin into metabolites mainly excreted with 
the urine [9]. In particular, through the catalysis mediated by IDO1, monoamine 
oxidases (MAO) or indolethylamine-N-methyltransferase (INMT), serotonin is 
converted into formyl-5-hydroxykynurenamine, 5-hydroxyindoleacetic acid and 
N-methylserotonin, respectively. Although rapidly metabolized, serotonin can be 
taken up by serotonin reuptake transporters (SERT) expressed in the CNS, platelets, 
GI and peripheral vasculature; once in the cytosol, the metabolite is immediately 
packaged into vesicles by vesicular monoamine transporter (VMAT) that prevents 
further degradation by mitochondrial MAO. Calcium-dependent exocytosis, such 
as that triggered during an inflammatory response or vascular injury, is responsible 
for the release of serotonin from the storing vesicles.
As an archetype of chronobiological hormone, melatonin is mainly produced by 
the pineal gland in response to circadian rhythm, i.e. the concentration of melato-
nin rises in the darkness and decreases in the daytime [10]. Along with melatonin, 
pineal NAS levels are higher at night than during the day, as opposed to pineal 
serotonin whose concentration peaks with the lightering. The rhythmic rotation 
between daily and nightly profiles of pineal indoles is controlled by the circadian 
clock located in the suprachiasmatic nuclei of the hypothalamus [11]. In homeo-
static conditions during the darkness, the norepinephrine-mediated activation of 
adrenergic receptors results in an increase of cytosolic calcium and cAMP, which 
activate the protein kinase A (PKA) with the consequent phosphorylation of the 
cAMP response element binding protein (CREB). Phosphorylated CREB migrates 
into the nucleus and induces the transcription of Aanat gene, thus fuelling the 
synthesis of NAS and melatonin. Moreover, PKA phosphorylates AANAT, protect-
ing the enzyme from the proteasomal degradation.
This central clock not only ensures the adaptation of living organisms to the 
cyclic and seasonal environmental changes, but also allows the efficient handling of 
immune responses [12]. If on one hand, pineal melatonin can regulate the immune 
responses and rhythmically vary the immune system’s components, on the other 
hand signals sent by immune cells can be perceived by pineal gland as feedback for 
the regulation of melatonin production [13, 14]. This back and forward switch in 
melatonin biosynthesis, namely immune-pineal axis, is considered the cornerstone 
of the neuroendocrine-immune network that allows the communication between 
immune, nervous and endocrine systems [15].
Pathogen-associated molecular patterns (PAMPs, such as bacterial lipopolysac-
charide and viral double stranded RNA) as well as danger-associated molecular 
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patterns (DAMPs; including tissue debris and amyloid β peptide) trigger the shift 
between pineal and extra-pineal melatonin synthesis. By interacting with their 
cognate receptors, PAMPs and DAMPs promote the nuclear translocation of the 
transcription factor nuclear factor κ-light-chain-enhancer of activated B cells 
(NF-κB), which binds to the promoter of target genes coding for pro-inflammatory 
mediators as well as of anti-inflammatory factors involved in the later recovery 
phase. Aanat is one of the genes whose transcription is regulated by NF-κB either 
positively or negatively, depending on cellular microenvironment. Specific NF-κB 
dimers allow the activation of the immune system in synch with the relocation of 
melatonin production from the pineal gland to the activated immune cells and vice 
versa. In the pinealocytes, the homodimer p50/p50 inhibits Aanat transcription, 
while in macrophages the heterodimer RelA/c-Rel induces Aanat gene expression 
and thus fuels the local melatonin production [16]. Whilst macrophages-derived 
melatonin promotes their migration to damaged tissue and enhances their phago-
cytic capacity, it is the indole metabolite itself that directly ends the process through 
the inhibition of NF-κB activity [17, 18]. The blockage of NF-κB re-establishes the 
homeostatic conditions and shifts the synthesis of melatonin from immune cells 
to pinealocytes. Moreover, during the recovery phase, melatonin is assisted by the 
adrenal cortex hormones (namely corticosteroids) in reducing the nuclear content 
of pineal p50/p50 homodimer, leading to an increase of Aanat transcription and 
thus more feed for melatonin synthesis [19].
3. Serotonin and its metabolites in immune cells
In the guise of both neurotransmitter and hormone, serotonin contributes to 
the regulation of several physiologic processes, such as central and peripheral 
functions, including sleep, mood and appetite as well as heart functionality, 
intestinal mobility and vascular tone among the most relevant. Accumulating 
evidences suggest that non-neuronal serotonin is also endowed with immu-
noregulatory properties. As a matter of fact, several immune cells possess the 
machinery to synthesize, store, respond to and take serotonin up from the micro-
environment [20]. Changes in serotonin levels have been reported in patients with 
chronic inflammation and autoimmune dysfunctions, including multiple sclerosis 
(MS), rheumatoid arthritis and inflammatory bowel disease [21]. Drugs that 
modulate serotonin signalling, such as the selective serotonin reuptake inhibi-
tors (SSRIs), appear to affect peripheral immunity. By blocking the reuptake of 
serotonin, SSRIs have found a place as anti-depressant in the clinical practice and 
only recently their ability to influence T lymphocytes proliferation, apoptosis and 
cytokines’ production has emerged [22].
3.1 Serotonin receptors expression in cells of the innate immune system
In mammals, seven families of serotonin receptor (5-HTRs) have been identi-
fied (Table 1) [23]. All 5-HTRs belong to the G-protein coupled receptor (GPCR) 
superfamily, with the exception of 5-HT3R, which is a ligand-gated ion channel 
permeable to calcium, sodium and potassium, whose activation leads to a rapid 
depolarization of the plasma membrane. The members of the GPCR-like serotonin 
receptors activate an intracellular signaling cascade that involves Adenylyl cyclase 
(AC) and phospholipase C (PLC) as effector systems [23]. 5-HT1R and 5-HT5R 
are negatively coupled with AC and thus their activation results in a reduced 
cAMP. Conversely, 5-HTRs 4, 6 and 7 are positively associated with AC with the 
consequent raise of cAMP levels. Upon serotonin binding, 5-HT2R signals through 
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PLC-mediated release of inositol triphosphate and diacylglycerol, which increases 
intracellular calcium levels.
By virtue of the ubiquitous expression of the 5-HTRs and the different intracel-
lular pathways activated, the biology of serotonin appears to be somewhat intricate 
and this accounts for its pleiotropic functions. 5-HTRs have been identified on 
murine and human innate immune cells, including neutrophils, monocytes, 
macrophages, dendritic cells (DCs), mast cells and natural killer cells [24]. The 
modulatory effects of serotonin on DCs depends on their maturity state, as 5-HTRs 
are differentially located on mature (mainly expressing 5-HT4R and 5-HT7R) and 
immature (expressing 5-HT1BR and 5-HT2BR) cells [25]. The overall literature 
agrees on the role of serotonin in modulating migration, morphology and cyto-
kines’ production by human and murine DCs. Through the activation of 5-HT4R 
and 5-HT7R, indeed, the monoamine affects the differentiation capacity of human 
monocytes to DCs, and increases the release of the anti-inflammatory cytokine 
IL-10, meanwhile the engagement of 5-HT7R results in increased expression of C-C 
chemokine receptor type 7 (CCR7), an important receptor involved in DCs migra-
tion [25, 26].
Although the expression of several 5-HTRs has been described in both human 
macrophages (5-HT1AR, 5-HT2AR, 5-HT2BR, 5-HT3R and 5-HT7R) and monocytes 
(5-HT2AR, 5-HT3R, 5-HT4R and 5-HT7R) at transcriptional level, only specific 
Target Subtype Ligand Type of immune cells expressed on
5-HT1R A Serotonin Mast cells, Monocytes, Macrophages, NK 
cells, T and B cells
B Immature DCs, T cells
E Immature DCs, Monocytes
5-HT2R A Monocytes, Macrophages, Eosinophils, T and 
B cells
B Monocytes, Macrophages, immature DCs
C Macrophages
5-HT3R Monocytes, Macrophages, DCs, T and B cells
5-HT4R Monocytes, Macrophages, mature DCs
5-HT5R Unknown
5-HT6R Unknown
5-HT7R Monocytes, Macrophages, mature DCs, T and 
B cells
MT1 Melatonin Monocytes, Macrophages, Nk cells, T cells
MT2
MT3 Melatonin, NAS Neutrophils
RORα/RORβ Melatonin T cells





TrKB NAS Neutrophils, Macrophages, DCs
IDO1 DCs
Table 1. 
Molecular targets of serotonin and metabolites thereof, and their expression on immune cells.
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subtypes have been confirmed by molecular and functional studies. Indeed, 
through 5-HT1AR, serotonin can induce the secretion of pro-inflammatory 
cytokines by peritoneal macrophages as well as boosts their phagocytic activity. 
Contrarily, by the engagement of 5-HT2BR and 5HT7R, serotonin promotes the 
polarization of human macrophages toward the anti-inflammatory phenotype [27]. 
The 5-HT1AR is the prevailing receptor involved in inducing mast cells adhesion 
to fibronectin and thus in promoting their recruitment to the inflammatory bed. 
Unlike to other innate immune cells, mast cells express TPH1 enzyme, thus they are 
able to deplete Trp from the microenvironment and de novo synthesise serotonin 
[28]. Thanks to the presence of SERT, mast cells, macrophages and DCs are able 
to take serotonin up, store it in vesicles and subsequently release it in a calcium-
dependent manner, in response to danger signals and inflammatory stimuli.
3.2 Serotonin receptors expression in cells of the adaptive immune system
Serotonin can shape the course of not only innate, but also adaptive immune 
responses, as demonstrated by its co-stimulatory role in the immunological synapse 
between DCs and T lymphocytes. By activating the 5-HT2BR expressed on inflam-
matory monocyte-derived DCs (moDCs), serotonin alters their cytokines’ profile 
and thus interferes with the differentiation of moDCs primed-CD4+ T cells toward 
the inflammatory Th1 and Th17 lymphocytes [29]. Besides indirectly affecting 
the activation of T cells, serotonin can activate the 5-HTRs expressed on T and B 
cells and thus directly influence their phenotype and functions. Pioneering stud-
ies have proposed that the stimulation of 5-HT1AR and 5-HT3R promotes T cells 
proliferation, while the blockage of 5-HT1BR with a specific antagonist decreases 
the cytokines’ production by T lymphocytes and their cell-mediated immunity [30]. 
In naive-T cells, signalling through the 5-HT7R induces the phosphorylation of the 
kinase ERK1/2 and activates the transcription factor NF-κB, converging in IL-2 
synthesis and T-cell proliferation [31].
In addition to 5-HTRs, T cells express the high affinity transporter SERT, whose 
modulation with the selective inhibitors (SSRIs) suppresses T cells proliferation and 
induces apoptosis [32]. Moreover, T lymphocytes possess all the machinery to store, 
produce and degrade serotonin, suggesting an autocrine and paracrine role of the 
monoamine in modulating T cells proliferation and function [33]. As in platelets, 
the secretory ability of T cells can be affected by intracellular serotonin via a process 
known as serotonylation, which is the covalent linking of serotonin to glutamine 
residues of small intracellular GTPases involved in the exocytosis. This process 
occurs right after the monoamine transport into the cell, involves the enzyme trans-
glutaminase for the creation of glutamyl-amide bonds, and results into a constitu-
tive activation of the G-protein dependent signalling cascade [34].
The complexity of peripheral serotonin has emerged since 1999, i.e. since, when 
applied to intestinal preparations, opposite effects appeared depending on the 
conditions [35]. The variety of serotonin functions outside the CNS seems to apply 
also to the role of the monoamine in the regulation of immune responses. Although 
numerous investigations have attempted to fill the gaps in such direction, the 
knowledge in this field remains yet incomplete [20].
3.3 Distribution of receptors for serotonin-derived metabolites in immune cells
Likewise serotonin, melatonin exhibits a functional versatility as it regulates 
several biologic processes, ranging from sleep and circadian rhythm to oxidative 
stress, age and immune function [10, 36, 37]. Mechanistically, the physiologic 
effects of melatonin can be achieved through the binding of membrane and nuclear 
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receptor as well as via receptor-independent pathways; the latter involving the 
interaction with cytoplasmic and mitochondrial proteins [38]. Three different 
subtypes of membrane receptor have been identified, i.e. melatonin receptor type 
1a (MT1), type 1b (MT2) and type 1c (MT3) (Table 1). With the exception of MT3 
(which is quinone reductase-2 enzyme), the melatonin membrane receptors belong 
to the GPCRs superfamily and are distributed in the CNS and, to a less extent, in 
cardiovascular system, colon, skin and immune cells. MT1 and MT2 are negatively 
coupled with AC and thus their activation results in a reduced production of cAMP 
and the consequent failure of PKA activation. The nuclear receptor signalling of 
melatonin is mediated via the transcription factor retinoid Z receptors and retinoid 
orphan receptors (RZR/ROR). RZR/ROR is an orphan member of the nuclear 
receptor superfamily, which encompasses the product of three genes: RORα, RORβ 
and RORγ. In immunocompetent cells, specific nuclear melatonin-binding sites 
have been reported, including RORα and RORβ in human lymphocytes, and RORα 
in both thymus and spleen of mice [39, 40].
Whilst the MT1/MT2 receptors are mainly responsible for the neuronal func-
tions of melatonin, the activation of both nuclear and membrane receptors appears 
to be primarily involved in the imunomodulatory and anti-tumor effects of the hor-
mone [41]. The exogenous administration of melatonin stimulates monocyte as well 
as macrophage production in both bone marrow and spleen of mice, by activating 
MT receptor and increasing the sensitivity of progenitors to stimulants such as IL-4 
and GM-CSF [42]. Human monocytes express both membrane and nuclear melato-
nin receptor, whose activation stimulates the production of the pro-inflammatory 
cytokines IL-1β, IL-6 and TNF-α, while decreases IL-10 [42]. By engaging MT1/
MT2 receptor, melatonin activates a mitogenic signal that counteracts the spontane-
ous apoptosis of circulating monocytes. The activity of melatonin with regard to 
macrophages translates into the inhibition of inducible nitric oxide synthase (iNOS) 
expression and blockage of COX-2 activity, with the consequent decrease of inflam-
matory mediators [43].
T lymphocytes express both membrane and nuclear receptors for melatonin, as 
well as all the machinery required for the synthesis and secretion of the hormone. 
Thus, is not surprising that melatonin impacts T cell biology, from the differentia-
tion to the functional activation, as demonstrated by the blunted proliferation of 
splenic lymphocytes in response to mitogenic signal when both the nuclear and 
the MT1/MT2 receptors are inhibited [44]. Melatonin, by directly interacting 
with RORα and promoting its degradation, regulates the expression of IL-2 [45]. 
Meanwhile, through the activation of MT1-dependent signalling pathway restrains 
the constitutive activity of RORα, thus further stimulating the IL-2 production 
[46]. Such a redundancy of the membrane and nuclear receptor is at the service of 
T cell differentiation as well. Although RORγt is the well-known lineage specific 
transcription factor for Th17 cells, it synergizes with RORα to enhance Th17 differ-
entiation. On one side, melatonin induces the degradation of nuclear RORα, while 
on the other, by binding MT1, it activates an intracellular signalling cascade that 
ends with the repression of the Rora and Rorc gene expression [47]. Depending on 
the immunological context, melatonin differentially controls T cells effector func-
tions, i.e. under immunosuppressive condition, melatonin stimulates the immune 
system, while it inhibits exacerbated immune responses. For instance, melatonin 
increases the number of regulatory T cells in both human and murine model of 
inflammatory/autoimmune diseases, such as systemic lupus erythematosus or MS; 
meanwhile it reduces the frequency of IFN-γ and IL-17 producing T lymphocytes 
[48–50].
For many years, NAS was thought to be merely an intermediate product in mela-
tonin biosynthesis. However, a series of non-overlapping activities of NAS as well 
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as different brain distribution of the metabolite - when compared to melatonin and 
serotonin - has given a precise biologic identity to this indole derivative. NAS, but 
not serotonin or melatonin, is an agonist of the tyrosine kinase B (TrkB) receptor of 
the brain-derived neurotrophic factor (BDNF), whose activation contributes to the 
antidepressant, cognition-enhancing and anti-apoptotic effect of NAS (Table 1) [51, 
52]. TrkB receptors are transmembrane proteins with an extracellular BDNF-binding 
domain and an intracellular tyrosine kinase domain that, once activated, undergoes 
autophosphorylation and subsequent coupling to intracellular signalling pathways. 
Through the activation of TrkB, NAS offers neuroprotection in experimental models 
of neurological injury and MS, which at least in part occurs by the mitigation of 
apoptosis and autophagic dysfunction [53, 54]. Additionally, NAS-mediated neuro-
immune modulatory effects can arise from the allosteric activation of the enzyme 
IDO1 [55]. The direct binding of NAS to a previously unknown allosteric site on 
IDO1 enhances the production of the immunoregulatory metabolite L-Kynurenine, 
which, in turn, by re-educating the immune system, ameliorates the disease symp-
toms in a mouse model of MS. Moreover, NAS displays a high affinity for the mela-
tonin MT3 receptor, which is a quinone reductase-2 enzyme and through which NAS 
exerts additional anti-oxidant and anti-depressant effects [56].
The metabolic product of melatonin, i.e. AFMK, is considered a potent tissue pro-
tector as it efficiently neutralizes reactive molecules and reduces lipid peroxidation 
and DNA damage [57]. AFMK acts as a reducing agent able to donate two electrons, 
in contrast with other physiological antioxidants that donate a single electron to neu-
tralize free radicals. Increased formation of AFMK is associated with inflammatory 
conditions, as the concentration of this kynuramine increases in the cerebrospinal 
fluid of patients with meningitis and the human epidermal keratinocytes exposed 
to UVB radiation [58, 59]. The raised levels of AFMK are consistent with its role as 
tissue protector and immune modulator. Indeed, AFMK is capable to attenuate the 
severity of acute pancreatic inflammation, by reducing pancreatic tissue damage and 
TNF-α serum concentration, and by increasing the activity of anti-oxidant enzymes 
[60]. Likewise melatonin, AFMK prevents COX-2 and iNOS activation induced by 
LPS in macrophages, and the production of TNF-α and IL-8 in activated neutrophils, 
thus exerts anti-inflammatory and immunomodulatory effects [61, 62].
No longer considered as merely neuronal mediators, the methoxyindoles 
metabolites are now emerging as key modulators of immune responses. Given the 
intrinsic complexity of the biological systems, the evolution has conserved and 
specialized the functions of each serotonin derivatives, making them able to work in 
the same direction or independently.
4. Role of serotonin in the gut-brain axis
Is “Butterflies in the stomach”, a metaphor or a real experience? From a physi-
ological point of view, butterflies are authentic visceral sensations coming from an 
unexpected source, which is the second brain. Hidden in the walls of the digestive 
system, this intestinal brain is also known as enteric nervous system (ENS). It’s 
generally thought that the ENS is the original nervous system that developed in 
the first vertebrates more than 500 million years ago and that has been conserved 
during the evolution to link digestion with mood and general organism’s fitness 
[63]. The human ENS contains more than 200 million neurons, distributed in many 
thousands of small ganglia, the great majority of which are found in two plexuses, 
the myenteric and submucosal plexuses. Its main role is controlling all the digestive 
process from the swallowing to the nutrient absorption and elimination. It does not 
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seem capable of common thoughts, but it can communicate back and forth with our 
big brain, creating the otherwise known “gut-brain axis”.
The bidirectional communication underlying the gut-brain axis includes the 
CNS, the autonomic nervous system, the ENS and the hypothalamic pituitary adre-
nal (HPA) axis. On one side, the autonomic nervous system drives both afferent and 
efferent signals arisen from the GI and the CNS, respectively. For its part, the HPA 
axis is activated by environmental stressors and promotes the cortisol release from 
the adrenal glands. Thus, by means of hormones and neurotransmitters, the brain 
controls the activity of intestinal effector cells, including epithelial cells, neurons, 
smooth muscle, enterochromaffin and immune cells. Recently, the gut microbiome 
has emerged as critical component of the gut-brain axis, handling not only the local 
intestinal functions, but also the distant CNS activities [64, 65].
Trp and its metabolite serotonin are the main nexus for the gut-brain-
microbiome axis. This link builds on the principles that (i) the manipulation of 
the microbiota composition across lifespan influences the Trp availability, (ii) the 
gut microbes can directly or indirectly affect the Trp metabolism and serotonergic 
signaling at the level of CNS to modulate behaviour, and (iii) serotonin influences 
the development of both ENS and CNS. Indeed, the gut microbiota can indirectly 
influence Trp availability by balancing the amino acid metabolism along the 
serotonin or the kynurenine pathway. Germ-free animals (i.e., microbiota-deficient 
mice raised in a sterile environment) exhibit a reduced IDO1 activity (as measured 
by the kyn/Trp ratio) as well as an increased central serotonin turnover, which both 
normalize following microbiota colonization immediately post-weaning [66, 67]. 
The gut microbiome can also directly affect the local and circulating Trp availability 
for the host, as some bacterial strains harbour the enzymes that can either utilize 
Trp to produce indole-derivatives (such as indole 3-acetic acid and indole-3-carbox-
aldehyde) or synthesize the amino acid on their own [68, 69].
Although mainly formed before the mid-gestation in the foetus, the central neu-
ronal circuitry is continuously subjected to genetic and environmental-mediated 
modifications until puberty. Serotonin is considered one of the signaling molecule 
that can regulate the development of CNS, among many other organs, as the lack 
of brain serotonin results into reduced body growth and improper central circuitry 
formation [70]. Changes in the serotonergic system occurs across the lifespan and a 
decreased uptake of the metabolite follows the aging [71]. Although, in the human 
brain, the levels of serotonin remain fairly stable, the overall serotonin receptors 
reduce by about 30–50% over the lifespan. Developmental changes of serotonergic 
system are mirrored by the variation of gut microbiota composition during the 
lifetime, as the infant gut microbiota tends to reach a stable adult-like configuration 
in the childhood - while completely changes in elderly subjects - and the early colo-
nization of the GI tract is fundamental for the proper development of the central 
serotonergic system [66].
Likewise the CNS, the ENS is capable of neurogenesis in post-natal and adult 
life. Such an intrinsic plasticity is mainly related to the exposure of the ENS to 
microbial, diet and inflammatory challenges that populate the intestinal lumen. 
Moreover, the normal process of aging contributes to such variability by increas-
ing the neuronal degeneration and cell death. In mice, the post-natal neurogenesis 
depends on the activation of 5-HT4Rs, whose expression affects the abundance 
of ENS neurons, while the differentiation of enteric nerve cells is conditioned by 
the activation of 5-HT2BR [72, 73]. In addition, stimulation of 5- HT4R inhibits 
inflammatory reactions, protects enteric neurons from apoptosis and promotes the 
mobilisation of adult stem cells to form new neurons that may replace damaged or 
dead ones [72].
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By involving neuronal, immune and endocrine mediators, the gut-brain-micro-
biome axis ensures the gut homeostasis as well as integrates the peripheral intestinal 
activities with emotions, cognitive functions and immune activation. As a matter of 
fact, people coping with inflammatory bowel disease or other intestinal issues (such 
as constipation, diarrhoea and abdominal pain) experience depression and anxiety, 
as a consequence of danger signals sent by an altered GI to the CNS. Noteworthy, 
these people receive benefit from antidepressants and mind–body therapies that 
help in smoothing negative signals coming from the GI tract. It is thus clear that 
not only the big brain is conscious of the ENS and of the gut microbiome, but the 
intestine as a whole can influence the perception of the world and alter human 
behaviour. Therefore, in coming years, physicians will need to expand their drugs 
pool to treat the “mental illness” of the big brain alongside of the second brain, in 
order to reach therapeutic profits in both behavioural and gastrointestinal diseases.
5.  Balancing act between Trp degradation pathways as a 
pharmacological target for CNS diseases
Serotonin biosynthesis is strictly related to tryptophan availability; in fact, Trp 
is metabolized not only along the serotonin pathway (SP), but also the kynuren-
ine pathway (KP). The importance of the maintenance of a homeostatic balance 
between KP and SP of Trp metabolism is underlined by the hypothesis that, in the 
CNS, some diseases, such as depression [74], Alzheimer’s [75] and Parkinson’s [76] 
are triggered by a shift of this equilibrium towards the KP; however, little is still 
known between the interplay between the two Trp metabolic pathways.
As mentioned above, the very existence of serotonin in different organs and tis-
sues is strongly conditioned by the expression and enzymatic activity of molecules 
belonging to the tryptophan-metabolizing family, which includes IDO1, tryptophan 
2,3-dioxygenase (TDO) and, according to much of the literature to date, IDO2 [77]. 
Nevertheless, the role of IDO2 as an enzyme capable of initiating the degradation of 
Trp along the KP probably derives from the erroneous interpretation of the struc-
tural analogy between IDO1 and IDO2; recently, this concept is being progressively 
revisited, and now the idea is emerging that IDO2 functions are linked to an activity 
other than the enzymatic one [78], which is almost negligible [79]. Thus, IDO1 and 
TDO represent the two key players determining the fate of Trp.
Trp depletion by TDO and IDO1 occurs via a mechanism that is well studied and 
has rather clear consequences: as a matter of fact, the catabolism of Trp to immu-
nosuppressive and neuroactive kynurenines is a key metabolic pathway regulating 
immune responses and neurotoxicity.
The KP initiated by IDO1 or TDO has two main branches (Figure 1). Under 
physiological conditions, Kyn is preferentially converted into 3-hydroxykynurenine 
(3HK) and then 3-hydroxyanthranilic acid (3HAA), quinolinic acid (QA), and 
ultimately NAD+. Alternatively, Kyn can be converted into kynurenic acid (KynA) 
by the kynurenine aminotransferase (KAT) enzymes [80].
KynA is generally considered to be neuroprotective; it competitively inhibits 
ionotropic glutamate receptors at high concentrations, and acts as a negative 
allosteric modulator at the α7-nicotinic receptor [81]. Moreover, KynA has also been 
shown to act as an agonist at an orphan G-protein-coupled receptor in neurons and 
astrocytes, leading to a suppression of several inflammatory pathways [82]. KynA 
also regulates the immune response through its agonistic effects on the aryl hydro-
carbon receptor (AhR), a transcription factor involved in the metabolism of xeno-
biotics. Numerous compounds have been proposed as putative endogenous AhR 
ligands, many of which are generated through pathways involved in the metabolism 
11
Serotonin Pathway in Neuroimmune Network
DOI: http://dx.doi.org/10.5772/intechopen.96733
of tryptophan and indole. Among them, besides the already mentioned KynA, Kyn, 
xanthurenic acid, cinnabarinic acid can also be counted, as well as indole derivatives 
mainly produced in the gut by microbial metabolism, such as indole-3-acetic acid 
(IAA), indole-3-aldeyde (IAld) and tryptamine; the activation of AhR by metabo-
lites produced downstream IDO1 or TDO may contribute to the modulation of the 
immune response both in periphery and CNS [83].
QA is an NMDA receptor agonist that can also inhibit the reuptake of glutamate 
by astrocytes leading to excitotoxicity, and exerts neurotoxic effects via several 
different mechanisms, including the generation of reactive oxygen species and 
the disruption of the blood brain barrier. In astrocytes, QA also potentiates the 
inflammatory response by inducing the production of proinflammatory mediators; 
moreover, QA may also activate microglia through NMDA receptors, a pathway that 
triggers neuronal cell death [81].
The two enzymes leading to the activation of the KP, TDO and IDO1 are local-
ized in different cells and tissues and are used in different physiological processes. 
Hepatic TDO regulates blood homeostasis of Trp and neuronal TDO influences 
neurogenesis. TDO-deficient mice show no peculiar phenotypes, but display altera-
tions in neurogenesis and anxiety-related behaviour. Moreover, TDO-deficiency or 
inhibition is neuroprotective in a murine model of MS, suggesting a role for TDO in 
the production of byproducts involved in the pathogenesis of neurological autoim-
mune diseases [84].
IDO1 is expressed in most tissues at low levels, including cells of the central ner-
vous system (CNS) and cells of the immune system, but not in the liver. The activity 
of IDO1 is more closely related to the modulation of the immune response than to 
the regulation of dietary levels of Trp, and, as in the case of TDO, is decisive in the 
production of neuroactive metabolites. The effects of Trp metabolism by IDO1 (or 
TDO) in immunity are complex, and can be shortly explained by four mechanisms: 
(i) by means of the so-called “Trp starvation”, that is, locally depleting Trp, which 
deprives tryptophan-dependent cells, such as proliferating T cells, of an essential 
amino acid; (ii) by the production of bioactive kynurenines; (iii) by regulating 
immune cell metabolism, for example, by feeding de novo NAD+ biosynthesis; 
and (iv) by means of a recently discovered signalling activity, through which IDO1 
becomes phosphorylated in its immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs), so to mediate intracellular signalling events in a self-sustaining feedfor-
ward loop leading to durable immunoregulatory effects [85]. All these mechanisms 
are involved on the potential development of neuropsychiatric disorders [83], since, 
as previously said, many kynurenines are neuroactive, modulating neuroplasticity 
and/or exerting neurotoxic effects. Thus, it is not surprising that KP is considered 
implicated in psychiatric illness in the context of inflammation, such as mood 
disorders (i.e., major depressive disorder - MDD), psychosis, schizophrenia, as well 
as in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease (all 
reviewed in [81]) and autoimmune diseases, such as MS.
Many efforts in drug development for neurodegenerative and neuropsychiatric 
diseases have focused on altering the overall balance of neuroactive KP metabo-
lites production through inhibition of enzymes involved in the formation of 
either QA or KA, or by means of synthetic molecules mimicking the effects of the 
endogenous compounds. The first clinical trials for MDD are currently ongo-
ing, assessing the effects of an analogous of KynA, AV-101 (NCT02484456 and 
NCT03078322). AV-101 is a selective antagonist at the glycine-binding site of the 
NMDA receptor [86].
Since Trp, Kyn, and 3HK can be transported across the blood brain barrier 
(BBB), and other KP metabolites possibly share the same feature [81], another 
potential target is the carrier facilitating the passage through the BBB, that is the 
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large amino acid transporter (LAT1). It has been recently demonstrated that leucine 
treatment is a feasible method of competitively blocking LAT1 to prevent exoge-
nous Kyn from entering into the brain [87]; on the basis of this observation, a phase 
2 clinical trial to test the anti-depressant effects of leucine in individuals with MDD 
is currently ongoing (NCT03079297). Nevertheless, recent findings suggest that 
several established treatments for depression also alter KP metabolism, as in case 
of the electro-convulsive therapy, which significantly increases circulating levels of 
KynA and KynA/3HK in depressed patients [88]. Another example is represented 
by Ketamine, used as treatment for MDD in selected population of patients, that 
was shown to acutely decrease circulating kyn and the Kyn/Trp [89].
However, besides the overt involvement of KP in the pathogenesis of several 
CNS diseases, how the production of kynurenines and the shift of the Trp metabo-
lism from SP towards KP affect the production of serotonin to date it is not clear, 
and it’s also a subject of intense investigation whether the reduced production of 
serotonin, and the molecules thereof, is involved in the pathogenesis of certain 
diseases. In the specific case of MDD, the Trp metabolism is considered to explain 
the aetiology and pathogenesis of depression. More specifically, the aetiology of 
MDD seems to rely on the concomitant manifestation of an imbalance between the 
Kyn pathway induced by IDO1 and the serotonin pathway, the neurotoxic effects 
of Kyn pathway metabolites and the persistent activation of the KP due to exposure 
to repeated and consistent stress. A further example of the close connection of 
neuronal and immune systems, and of the importance of a balance between the 
two branches of Trp metabolism for the maintenance of a health status, can be 
represented by depression related to cancer. A simplistic and nowadays outdated 
vision of the immunological asset of cancer patients proposed that one of the major 
causes of depression in cancer patients could be related to their apparent immuno-
suppressive general status; today this perspective is gradually undermined by the 
awareness that in many types of cancer, chronic inflammation is a common feature. 
Trp breakdown, and the subsequent reduction of the production of serotonin and 
metabolites thereof, due to the enhanced activation of enzymes of the KP, seems to 
be related to the prevalence of depressive disorders in cancer patients, since many 
patients often show decreased plasma Trp levels and increased kyn concentra-
tions [90]. In line with this hypothesis, and with the identification of IDO1 as an 
authentic immune checkpoint target for the immunopharmacological treatment of 
cancer [91], inhibition of IDO1 and/or TDO seems to be a promising strategy for the 
treatment of cancer-related fatigue and depression, with the aim of restoring the 
physiological balance between the KP and the SP [92].
Moreover, there is an additional factor to consider: not only the functional 
activity of IDO1/TDO can push the balance towards a decreased production of 
serotonin, but also the production of specific serotonin metabolites can, in turn, 
affect this balance, in favour of a sustained production of kynurenines. This is the 
case of NAS. As previously mentioned, a consistent part of the antidepressant and 
neurotrophic actions of NAS is due to its capability to activate the TrkB receptor; 
nevertheless, very recently, additional exciting mechanisms of action of NAS have 
been demonstrated, unveiling its role as an immunomodulatory molecule. In fact, 
NAS and melatonin have potent anti-oxidant, anti-inflammatory and neuroprotec-
tive properties in several animal models of neurological injury and disease, includ-
ing MS [53]. When administered in vivo in a murine model of multiple sclerosis, 
experimental autoimmune encephalomyelitis (EAE), melatonin and NAS reduced 
the loss of mature oligodendrocytes, demyelination and axonal injury, significa-
tively ameliorating the disease symptoms and progression. Both compounds also 
significantly attenuated iNOS induction and reactive oxygen species (ROS) genera-
tion in lipopolysaccharide-activated microglia in culture [53].  
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Moreover, NAS is capable of inducing DCs to acquire an immunosuppressive 
phenotype, which requires the presence and functional activity of the enzyme 
IDO1. Very interestingly, NAS has been demonstrated to function as a positive 
allosteric modulator of the enzyme IDO1 binding a recently identified allosteric site 
thus increasing the catalytic efficacy, but not the binding affinity of IDO1 toward 
its substrate Trp [55]. Moreover, the effects of NAS have been demonstrated not 
only in murine DCs, but also in peripheral blood mononuclear cells from a specific 
subset of MS patients, that is RR-MS patients, opening the possibility for the iden-
tification of an innovative and safe immunomodulating therapy for MS. NAS is the 
first-identified indole derivative of the SP acting as an endogenous IDO1 positive 
allosteric modulator (PAM). It is noteworthy that Trp shows an opposite behav-
iour, acting as an IDO1 negative allosteric modulator (NAM) when present at high 
concentrations [93]. Therefore, although kynurenines acting as endogenous PAMs 
for the enzymes of the serotonin pathway have not been identified yet, it is possible 
to speculate that products downstream of the KP and the SP might guarantee an 
appropriate equilibrium between the two main metabolic routes of Trp metabolism 
by allosteric mechanisms. This hypothesis may have important relevance for the 
design of innovative therapeutic strategies not only for the treatment of inflam-
matory/autoimmune CNS diseases, such as MS, but also for diseases involving an 
altered regulation of Trp metabolism. As an example, the therapeutic use of potent 
orthosteric inhibitors of IDO1 for the cancer immunotherapy could be hampered 
by the induction of a skewing toward the serotonin pathway and thus an excess 
production of immunoregulatory NAS. Regarding the possibility of rethinking the 
therapeutic approach for CNS inflammatory/autoimmune diseases, such as MS, that 
is immunosuppression, the development of PAMs selective for the IDO1 enzyme 
and therapeutically active in vivo may provide unprecedented opportunities to 
develop therapeutic agents with a considerably more limited number of undesirable 
effects than the conventional immunosuppressive therapy.
A cross-regulation of the two metabolic pathways of Trp degradation is 
performed not only by NAS, but also by its derivative melatonin. As previously 
said, melatonin can be used by the enzyme IDO1 as a substrate, giving rise to the 
production of AFMK, a metabolite endowed with anti-inflammatory properties. 
The effects of AFMK on expression and functional activity of Trp metabolizing 
enzymes are still unknown, if there are any. Melatonin not only can be metabolized 
by IDO1, but is capable of inducing the expression of the IDO1 gene in fibroblasts, 
melanocytes and in adrenal pheochromocytoma cells. In the latter model, silencing 
of IDO1 gene triggered the up-regulation of the expression of AANAT gene [94], 
and the overexpression of IDO1, in turns, led to the down-regulation of AANAT, 
meaning that, in specific cellular subsets, a strictly interconnection occurs between 
the two Trp degradation pathways. In the same study, melatonin induced an up-
regulation of the IDO1 expression, through the JAK-STAT2 signaling pathway, and 
of its enzymatic activity.
Moreover, melatonin is a competitive inhibitor, whereas serotonin is an allosteric 
inhibitor of the enzyme TDO [95] and although the biological significance of this 
effects has not been unveiled, it can be speculated that, in the CNS, inhibition of 
TDO by two metabolites of the SP could contribute to a shift of the balance of Trp 
consumption through the SP, depending on microenvironmental factors.
Overall, a huge number of pharmacological interventions for CNS diseases 
targeting Trp metabolism have been developed or are currently under investigation 
(reviewed in [96]), ranging from the inhibition of specific enzymes along the KP 
to the modulation of AhR signalling or administration of KYNA and its deriva-
tives [96]; nevertheless, the interconnections between the major pathways of Trp 
metabolism remain an open question.
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6. Concluding remarks
Bidirectional interactions between the nervous system and immune system, 
known as the “neuroimmune system”, regulate a wide range of physiological and 
pathological processes [1] and there is a huge literature linking general neuroinflam-
mation to neuropsychiatric disorders, such as depression [97], schizophrenia [98], 
but also MS [99], Alzheimer’s [100] and Parkinson’s disease [101]. Specific neuro-
immune factors, such as Trp derivatives, have been shown to modulate neuronal 
activity and complex behavioral processes and to create a functional bridge con-
necting the neuroendocrine and the immune systems. For this reason, serotonin and 
its derivatives, and the metabolic processes leading to the production of serotonin 
rather than kyn, are involved in the pathogenesis of various CNS diseases. Thus, it’s 
easy to imagine how Trp metabolism, and mostly the pursuit of an optimal balance 
between the two Trp metabolic pathways, may be a promising therapeutic target 
for a manifold spectrum of CNS pathologies. However, there is need for an in-depth 
knowledge of the mechanisms leading to one or the other Trp metabolic fate, and it’s 
also necessary to unveil their interconnections to define the appropriate interven-
tion for each specific disease, and to have the ability to precisely act on the targeted 
metabolite or enzyme.
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